Dermata Therapeutics (DRMA) Amortizatization of Intangibles (2020 - 2021)
Dermata Therapeutics (DRMA) posted quarterly Amortizatization of Intangibles of $155.0 for Q3 2021, down 99.04% year-over-year from $16134.0 in Q3 2020, and up 98.72% quarter-over-quarter from $78.0 in Q2 2021.
Dermata Therapeutics (DRMA) Amortizatization of Intangibles (2020 - 2021) Analysis & Trends
Dermata Therapeutics' Amortizatization of Intangibles history runs 2 years deep, the most recent figure standing at $155.0 for Q3 2021.
- In Q3 2021, Amortizatization of Intangibles fell 99.04% year-over-year to $155.0; the TTM figure through Jun 2022 stood at $155.0 (down 99.6% YoY), while the FY2021 annual figure was $14126.0, down 85.45% from the prior year.
- Amortizatization of Intangibles for Q3 2021 stood at $155.0, up from $78.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $16134.0 in Q3 2020, with the low at $78.0 in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 155.00 |
| Sep 30, 2021 | 155.00 |
| Jun 30, 2021 | 78.00 |
| Jun 30, 2021 | 78.00 |
| Mar 31, 2021 | 13,892.00 |
| Mar 31, 2021 | 13,892.00 |
| Dec 31, 2020 | 8,811.00 |
| Dec 31, 2020 | 8,811.00 |
| Sep 30, 2020 | 16,134.00 |
| Sep 30, 2020 | 16,134.00 |